<DOC>
	<DOCNO>NCT01376739</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Magnevist dose 0.2 ml/kg MR angiography peripheral vasculature continuous image abdomen low extremity . The objective study ass safety , especially relation renal dysfunction , efficacy use Magnevist clinical practice . A total 2,000 patient recruit .</brief_summary>
	<brief_title>Magnevist Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<criteria>Patients receive dose 0.2 mg/kg Magnevist MR angiography peripheral vasculature continuous image abdomen low extremity Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Magnevist</keyword>
	<keyword>MR angiography</keyword>
</DOC>